Close Menu
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
What's Hot

Fintech evolution paves the way for global banks to set up in Hong Kong: HKMA

September 18, 2025

HSBC cuts prime lending rate in first relief for borrowers since December

September 18, 2025

Breaking | Tech war: Huawei bypasses Nvidia AI chips in computing breakthrough for China

September 18, 2025
Facebook X (Twitter) Instagram
Thursday, September 18
Facebook X (Twitter) Instagram
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
World Economist – Global Markets, Finance & Economic Insights
Home » Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment
Business

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

adminBy adminJuly 1, 2007No Comments1 Min Read
Share Facebook Twitter Pinterest Copy Link LinkedIn Tumblr Email VKontakte Telegram
Share
Facebook Twitter Pinterest Email Copy Link
Post Views: 83


By Daniella Parra

Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List.

Olverembatinib, is first-line treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with low-intensity chemotherapy, Ascentage said.

Ph+ ALL, which accounts for 20%-30% of adult ALL cases, has poor treatment tolerance and prognosis, with existing first- and second-generation tyrosine kinase inhibitors (TKIs) facing limitations such as high relapse rates, they said.

“We are much encouraged to have olverembatinib’s clinical value once again recognized by the regulatory authority in China,” Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said. “This BTD underscores the therapeutic potential and utility of olverembatinib in Ph+ ALL, a hematologic malignancy with dismal prognosis. Moving forward, we will strive to accelerate this clinical development program for olverembatinib and bring it to more patients as quickly as possible.”

Contact:

Exec Edge

Editor@executives-edge.com



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Telegram Copy Link
admin
  • Website

Related Posts

Business

Fintech evolution paves the way for global banks to set up in Hong Kong: HKMA

September 18, 2025
Business

Breaking | Tech war: Huawei bypasses Nvidia AI chips in computing breakthrough for China

September 18, 2025
Business

Hong Kong stocks slip as Fed’s priced-in rate cut fails to excite investors

September 18, 2025
Business

Breaking | Hong Kong cuts base rate for the first time in 2025, matching the Fed’s move amid weak US jobs

September 17, 2025
Business

Ex-Ecuador president calls bribery case over Belt and Road dam a ‘farce’

September 17, 2025
Business

Tech war: Alibaba-developed AI processor on par with Nvidia’s H20 chip, CCTV report shows

September 17, 2025
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Indonesian envoy highlights various sectors for trade – Business & Finance

September 18, 2025

TOMCL secures USD7.5m orders to supply beef to China – Business & Finance

September 18, 2025

Ben & Jerry’s co-founder quits – Business & Finance

September 18, 2025

Loans only provide temporary relief, says Gohar Ejaz – Business & Finance

September 17, 2025
Latest Posts

PSX hits all-time high as proposed ‘neutral-to-positive’ budget well-received by investors – Business

June 11, 2025

Sindh govt to allocate funds for EV taxis, scooters in provincial budget: minister – Pakistan

June 11, 2025

US, China reach deal to ease export curbs, keep tariff truce alive – World

June 11, 2025

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Recent Posts

  • Fintech evolution paves the way for global banks to set up in Hong Kong: HKMA
  • HSBC cuts prime lending rate in first relief for borrowers since December
  • Breaking | Tech war: Huawei bypasses Nvidia AI chips in computing breakthrough for China
  • Is video on Prabowo’s goals in Indonesian cinemas propaganda or public service?
  • After Fed rate cut, only moderate easing expected by China’s central bank, supporting yuan

Recent Comments

No comments to show.

Welcome to World-Economist.com, your trusted source for in-depth analysis, expert insights, and the latest news on global finance and economics. Our mission is to provide readers with accurate, data-driven reports that shape the understanding of economic trends worldwide.

Latest Posts

Fintech evolution paves the way for global banks to set up in Hong Kong: HKMA

September 18, 2025

HSBC cuts prime lending rate in first relief for borrowers since December

September 18, 2025

Breaking | Tech war: Huawei bypasses Nvidia AI chips in computing breakthrough for China

September 18, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Archives

  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • June 2024
  • October 2022
  • March 2022
  • July 2021
  • February 2021
  • January 2021
  • November 2019
  • April 2011
  • January 2011
  • December 2007
  • July 2007

Categories

  • AI & Tech
  • Asia
  • Banking
  • Business
  • Business
  • China
  • Climate
  • Computing
  • Economist Impact
  • Economist Intelligence
  • Economy
  • Editor's Choice
  • Europe
  • Europe
  • Featured
  • Featured Business
  • Featured Climate
  • Featured Health
  • Featured Science & Tech
  • Featured Travel
  • Finance & Economics
  • Health
  • Highlights
  • Markets
  • Middle East
  • Middle East & Africa
  • Middle East News
  • Most Viewed News
  • News Highlights
  • Other News
  • Politics
  • Russia
  • Science
  • Science & Tech
  • Social
  • Space Science
  • Sports
  • Sports Roundup
  • Tech
  • This week
  • Top Featured
  • Travel
  • Trending Posts
  • Ukraine Conflict
  • Uncategorized
  • US Politics
  • USA
  • World
  • World & Politics
  • World Economy
  • World News
© 2025 world-economist. Designed by world-economist.
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.